Australia's most trusted
source of pharma news
Wednesday, 22 January 2025
Posted 17 January 2025 AM
Two companies - Moderna and Lilly - trimmed their sales forecasts this week and investors weren't happy, sending their respective share prices into a fall.
Moderna cut its 2025 revenue estimate by US$1 billion as it continues to wrestle with a diminishing Covid vaccine market and a slower than hoped RSV launch. The company's stock dropped 20 per cent on the news.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.